Spirea raises £2.4M to develop antibody drug conjugates in cancer
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
21-Jun-2022 -
Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million ($3M) with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of ...
antibody-drug conjugate
cancer
cancer therapeutics
+1